International Journal of Rheumatic Diseases

LETTER TO THE EDITOR

Case report: A case of resistant anti-SAE1 dermatomyositis with severe periorbital edema after hydroxychloroquine that responded to adalimumab

Corresponding Author

Maria Farhat

[email protected]

orcid.org/0009-0003-4375-5489

Dermatology Department, Faculty of Medicine, Saint Joseph University, Hôtel-Dieu de France University Hospital, Beirut, Lebanon

Correspondence

Maria Farhat, Dermatology Department, Faculty of Medicine, Saint Joseph University, Hôtel-Dieu de France University Hospital, Beirut, Lebanon.

Email: [email protected]

Search for more papers by this author

Boutros Soutou,

Boutros Soutou

orcid.org/0000-0002-3906-7021

Dermatology Department, Faculty of Medicine, Saint Joseph University, Hôtel-Dieu de France University Hospital, Beirut, Lebanon

Search for more papers by this author

Maria Farhat,

Corresponding Author

Maria Farhat

[email protected]

orcid.org/0009-0003-4375-5489

Dermatology Department, Faculty of Medicine, Saint Joseph University, Hôtel-Dieu de France University Hospital, Beirut, Lebanon

Correspondence

Maria Farhat, Dermatology Department, Faculty of Medicine, Saint Joseph University, Hôtel-Dieu de France University Hospital, Beirut, Lebanon.

Email: [email protected]

Search for more papers by this author

Boutros Soutou,

Boutros Soutou

orcid.org/0000-0002-3906-7021

Dermatology Department, Faculty of Medicine, Saint Joseph University, Hôtel-Dieu de France University Hospital, Beirut, Lebanon

Search for more papers by this author

First published: 19 March 2024

https://doi.org/10.1111/1756-185X.15125

Share a link

Email
Wechat
Bluesky

No abstract is available for this article.

Open Research

DATA AVAILABILITY STATEMENT

The data used to support the findings of this letter are included within the article.

REFERENCES

1De Vries M, Schreurs MWJ, Ahsmann EJM, et al. A case of anti-SAE1 dermatomyositis. Case Reports Immunol. 2022; 2022:9000608.
10.1155/2022/9000608
PubMed Web of Science® Google Scholar
2Albayda J, Mecoli C, Casciola-Rosen L, et al. A north American cohort of anti-SAE dermatomyositis: clinical phenotype, testing, and review of cases. ACR Open Rheumatol. 2021; 3(5): 287-294.
10.1002/acr2.11247
PubMed Web of Science® Google Scholar
3Hassan N, Davies EJ, Faber BG, Gunawardena H. Infliximab in a patient with treatment-resistant anti-SAE dermatomyositis. Rheumatology. 2021; 60(5): e156-e158.
10.1093/rheumatology/keaa698
PubMed Web of Science® Google Scholar
4Inoue S, Okiyama N, Shobo M, et al. Diffuse erythema with ‘angel wings’ sign in Japanese patients with anti-small ubiquitin-like modifier activating enzyme antibody-associated dermatomyositis. Br J Dermatol. 2018; 179(6): 1414-1415.
10.1111/bjd.17026
CAS PubMed Web of Science® Google Scholar
5Wolstencroft P, Casciola-Rosen L, Fiorentino D. Association between autoantibody phenotype and cutaneous adverse reactions to hydroxychloroquine in dermatomyositis. JAMA Dermatol. 2018; 154(10):1199.
10.1001/jamadermatol.2018.2549
PubMed Web of Science® Google Scholar
6Gono T, Tanino Y, Nishikawa A, et al. Two cases with autoantibodies to small ubiquitin-like modifier activating enzyme: a potential unique subset of dermatomyositis-associated interstitial lung disease. Int J Rheum Dis. 2019; 22(8): 1582-1586.
10.1111/1756-185X.13593
PubMed Web of Science® Google Scholar
7Jia E, Wei J, Geng H, et al. Diffuse pruritic erythema as a clinical manifestation in anti-SAE antibody-associated dermatomyositis: a case report and literature review. Clin Rheumatol. 2019; 38(8): 2189-2193.
10.1007/s10067-019-04562-w
PubMed Web of Science® Google Scholar

Volume27, Issue3

March 2024

e15125

Case report: A case of resistant anti-SAE1 dermatomyositis with severe periorbital edema after hydroxychloroquine that responded to adalimumab

Open Research

DATA AVAILABILITY STATEMENT

REFERENCES

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Case report: A case of resistant anti-SAE1 dermatomyositis with severe periorbital edema after hydroxychloroquine that responded to adalimumab

Open Research

DATA AVAILABILITY STATEMENT

REFERENCES

References

Related

Information